Intravenous Prophylaxis against urothelial toxicity
Adult: Calculate dosage equivalent to 20% w/w of the IV bolus dose of oxazaphosphorine (ifosfamide or cyclophosphamide), given simultaneously over 15-30 minutes. Repeat dose at 4 and 8 hours after the first dose. Dose may increase to 40% of the antineoplastic dose, given for 4 doses at 3 hourly intervals (0,3,6,9 hours), if necessary. Child: Shortened interval between doses and/or increased individual doses may be required.
Oral Prophylaxis against urothelial toxicity
Adult: Calculate dosage equivalent to 40% w/w of the IV bolus dose of oxazaphosphorine (ifosfamide or cyclophosphamide), given 2 hours before, then 2 and 6 hours after antineoplastic admin (total 3 doses). Child: Shortened interval between doses and/or increased individual doses may be required.
May be taken with or without food.
IV: Incompatible with platinum derivatives (e.g. carboplatin, cisplatin, nitrogen mustard) and epirubicin.
Patient with autoimmune disorders, urothelium damage associated with oxazaphosphorines or pelvic irradiation, conditions associated with inadequate response at standard doses (e.g. history of urinary tract disease), history of hypersensitivity to thiol compounds. Children. Pregnancy and lactation.
Significant: Dermatological toxicities [e.g. rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis]; haematuria. Blood and lymphatic system disorders: Lymphadenopathy. Cardiac disorders: Palpitations, chest pain, dyspnoea. Eye disorders: Conjunctivitis, photophobia, blurred vision. Gastrointestinal disorders: Abdominal pain or colic, diarrhoea, nausea, vomiting, dry mouth, mucosal irritation, constipation, flatulence, gingival bleeding, epigastric pain or burning. General disorders and administration site conditions: Fatigue, malaise, pyrexia, infusion site reactions (IV), influenza-like illness. Hepatobiliary disorders: Increased transaminase levels. Immune system disorders: Bronchospasm. Metabolism and nutrition disorders: Decreased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, back pain, pain in extremity, pain in jaw, rigors. Nervous system disorders: Headache, light headedness, lethargy or drowsiness, dizziness, paraesthesia, hyperesthesia, hypoesthesia, syncope. Psychiatric disorders: Disturbance in attention. Renal and urinary disorders: Dysuria. Respiratory, thoracic and mediastinal disorders: Epistaxis, nasal congestion, cough, laryngeal discomfort, pleuritic pain, hypoxia, respiratory distress. Skin and subcutaneous tissue disorders: Rash, pruritus, hyperhidrosis. Vascular disorders: Flushing. Potentially Fatal: Hypersensitivity (e.g. anaphylaxis, severe bullous and ulcerative skin).
May cause false positive reactions in nitroprusside sodium-based urine tests (e.g. dipstick tests) for ketone bodies. May cause false positive reactions in Tillman’s reagent-based urine screening tests for ascorbic acid. May interfere with enzymatic creatine phosphokinase (CPK) activity tests that use a thiol compound for CPK reactivation thus, may result in a falsely low CPK level.
Description: Mesna is first oxidized into mesna-disulphide or dimesna which is then reduced back into mesna in the renal tubuli epithelium. In the urine, mesna supplies free thiol group that reacts chemically with urotoxic oxazaphosphorine metabolites (e.g. acrolein) of ifosfamide and cyclophosphamide thereby reducing incidence of toxicities (e.g. haemorrhagic cystitits and haematuria) and enhancing excretion of cysteine which may increase uroprotective effect. Pharmacokinetics: Absorption: Bioavailability: 58% (range: 45-71%) as free mesna. Time to peak plasma concentration: 1.5-4 hours (free mesna). Distribution: Volume of distribution: 0.65 ± 0.24 L/kg. Plasma protein binding: 60-75%. Metabolism: Rapidly metabolised via oxidation into mesna-disulphide or dimesna in the intravascular compartment. Excretion: Via urine (32% as mesna, 33% as dimesna). Elimination half-life: Approx 22 minutes (mesna), approx 70 minutes (dimesna).
V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Anon. Mesna. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 26/07/2017.Anon. Mesna. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 26/07/2017.Buckingham R (ed). Mesna. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 26/07/2017.Joint Formulary Committee. Mesna. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 26/07/2017.Mesna Injection 1 g/10 mL (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/07/2017.Mesnex® Mesna Tablets 400 mg (Baxter Healthcare Ltd). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/07/2017.